(NASDAQ: REPL) Replimune Group's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.85%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.43%.
Replimune Group's revenue in 2024 is $0.On average, 5 Wall Street analysts forecast REPL's revenue for 2026 to be $1,092,869,050, with the lowest REPL revenue forecast at $136,642,792, and the highest REPL revenue forecast at $1,922,564,083. On average, 4 Wall Street analysts forecast REPL's revenue for 2027 to be $6,794,016,261, with the lowest REPL revenue forecast at $1,140,967,313, and the highest REPL revenue forecast at $12,683,183,953.
In 2028, REPL is forecast to generate $13,156,172,978 in revenue, with the lowest revenue forecast at $5,260,747,492 and the highest revenue forecast at $20,413,066,697.